ATRX mutations, innate immune activation and therapeutic vulnerability in malignant gliomas

ATRX 突变、先天免疫激活和恶性胶质瘤的治疗脆弱性

基本信息

  • 批准号:
    10666347
  • 负责人:
  • 金额:
    $ 37.7万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-08-01 至 2027-07-31
  • 项目状态:
    未结题

项目摘要

ABSTRACT Gliomas, including oligodendroglioma and astrocytoma subtypes, are a diverse group of malignant primary brain tumors that respond to radiation, surgery and chemotherapy; however, relapse remains a major barrier affecting overall patient survival. Immunotherapy targeting the adaptive immune system such as checkpoint inhibitors has shown limited efficacy in gliomas. Thus, understanding the immunobiology of gliomas and mechanisms of resistance to immune therapies is crucial to therapeutically leverage the immune system for treating patients. Our long-term goal is to dissect the innate immune system in gliomas and identify vulnerabilities that can be exploited for designing therapies. Recent studies have implicated a link between mutations in ATRX, a SWI-SNF chromatin remodeler and immune cell infiltration in the tumor microenvironment of ATRX-mutant astrocytomas. Our preliminary data suggest that ATRX inactivation in gliomas leads to enriched inflammatory signatures and potentiation of type I interferon/pro-inflammatory signaling, and selective sensitization of tumors to double-stranded (dsRNA)-based immune agonists. Based on these preliminary findings, we hypothesize that ATRX inactivation induces innate inflammation and sensitizes tumors to immune surveillance and dsRNA agonist therapy; concurrent IDH mutations suppress innate inflammation to enable tumor immune evasion. We will test our hypothesis in the following specific aims. Aim 1: Define the role of ATRX inactivation in modulating glioma cell-intrinsic innate signaling; Aim 2: Elucidate the role of ATRX deficiency and concurrent IDH1R132H mutation in modulating anti- tumor immunity and the response to dsRNA agonist therapy in pre-clinical murine glioma models; Aim 3: Determine the extent to which dsRNA-based therapies induce inflammatory activation of lower-grade gliomas. Our proposal will: 1) delineate the novel role of ATRX loss in regulating innate immune signaling responses and their downstream effects in glioma, 2) examine the immunological interplay between ATRX mutations and its partner mutation, IDH1R132H and 3) lay preclinical groundwork for exploiting a potential therapeutic vulnerability in gliomas carrying ATRX mutations.
摘要

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

David M. Ashley其他文献

Phase II study of carboplatin (CBDCA) in progressive low-grade gliomas.
卡铂 (CBDCA) 在进行性低级别胶质瘤中的 II 期研究。
  • DOI:
  • 发表时间:
    1998
  • 期刊:
  • 影响因子:
    4.1
  • 作者:
    Albert Moghrabi;Henry S Friedman;David M. Ashley;K. Bottom;T. Kerby;Elizabeth A. Stewart;Carol S. Bruggers;James M. Provenzale;Martin A. Champagne;Linda Hershon;M. Watral;Janis Ryan;Karima Rasheed;Shelley Lovell;David N. Korones;Herbert E. Fuchs;Timothy M George;R. McLendon;A. Friedman;Edward G. Buckley;D. Longee
  • 通讯作者:
    D. Longee
Brain immunology and immunotherapy in brain tumours
脑肿瘤中的脑免疫学与免疫疗法
  • DOI:
    10.1038/s41568-019-0224-7
  • 发表时间:
    2019-12-05
  • 期刊:
  • 影响因子:
    66.800
  • 作者:
    John H. Sampson;Michael D. Gunn;Peter E. Fecci;David M. Ashley
  • 通讯作者:
    David M. Ashley
A peptide vaccine targeting the CMV antigen pp65 in children and young adults with recurrent high-grade glioma and medulloblastoma: a phase 1 trial
针对患有复发性高级别胶质瘤和髓母细胞瘤的儿童和青少年的针对巨细胞病毒抗原 pp65 的肽疫苗:一项 1 期试验
  • DOI:
    10.1038/s43018-025-00998-z
  • 发表时间:
    2025-06-12
  • 期刊:
  • 影响因子:
    28.500
  • 作者:
    Eric M. Thompson;David M. Ashley;Katayoun Ayasoufi;Pamela Norberg;Gerald Archer;Evan D. Buckley;James E. Herndon;Ashley Walter;Bridget Archambault;Charlene Flahiff;Denise Jaggers;Laura Gorski;Luis A. Sanchez;Kendra Congdon;Kelly Hotchkiss;Sarah L. Cook;Eliese Moelker;Gordana Vlahovic;Elizabeth Reap;Kristin Schroeder;Dina Randazzo;Annick Desjardins;Margaret O. Johnson;Katherine Peters;Mustafa Khasraw;Henry Friedman;Duane A. Mitchell;John H. Sampson;Daniel Landi
  • 通讯作者:
    Daniel Landi
The evolution of the histology in pleomorphic xanthoastrocytomas in children: a study of 15 cases
儿童多形性黄色星形细胞瘤15例组织学演变
  • DOI:
    10.1097/pat.0b013e328340bb98
  • 发表时间:
    2011
  • 期刊:
  • 影响因子:
    4.5
  • 作者:
    Xiangru Wu;P. Bandopadhayay;J. Ng;David M. Ashley;C. Chow
  • 通讯作者:
    C. Chow
Evolocumab as an immunomodulator in glioma: A window of opportunity trial evaluating PCSK9 inhibition to enhance surface MHC-I on tumor
Evolocumab 作为神经胶质瘤的免疫调节剂:评估 PCSK9 抑制以增强肿瘤表面 MHC-I 的机会之窗试验
  • DOI:
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Kirit Singh;Matthew W. Foster;Marlene J. Violette;K. Hotchkiss;C. Railton;E. Blandford;Kathryn E. Blethen;Elizabeth L. Thomas;David M. Ashley;A. Desjardins;Henry Friedman;Margaret O. Johnson;Allan Friedman;Stephen T Keir;E. Buckley;James Herndon;R. McLendon;John H. Sampson;Evan Calabrese;Giselle Y. Lopez;Gerald A. Grant;Anoop P. Patel;Chuan;P. Fecci;M. Khasraw;The Preston
  • 通讯作者:
    The Preston

David M. Ashley的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('David M. Ashley', 18)}}的其他基金

ATRX mutations, innate immune activation and therapeutic vulnerability in malignant gliomas
ATRX 突变、先天免疫激活和恶性胶质瘤的治疗脆弱性
  • 批准号:
    10375084
  • 财政年份:
    2022
  • 资助金额:
    $ 37.7万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10488238
  • 财政年份:
    2021
  • 资助金额:
    $ 37.7万
  • 项目类别:
6-thio-2'-deoxyguanosine: A Novel Immunogenic Telomerase-Mediated Therapy in Glioblastoma - A Duke and UTSW Collaboration
6-硫代-2-脱氧鸟苷:一种新型免疫原性端粒酶介导的胶质母细胞瘤疗法 - 杜克大学和 UTSW 合作
  • 批准号:
    10305565
  • 财政年份:
    2021
  • 资助金额:
    $ 37.7万
  • 项目类别:
6-thio-2'-deoxyguanosine in GBM: Pre-clinical Evaluation of Mechanism of action, Efficacy and Biomarker identification
GBM 中的 6-硫代-2-脱氧鸟苷:作用机制、功效和生物标志物鉴定的临床前评估
  • 批准号:
    10488242
  • 财政年份:
    2021
  • 资助金额:
    $ 37.7万
  • 项目类别:
6-thio-2'-deoxyguanosine: A Novel Immunogenic Telomerase-Mediated Therapy in Glioblastoma - A Duke and UTSW Collaboration
6-硫代-2-脱氧鸟苷:一种新型免疫原性端粒酶介导的胶质母细胞瘤疗法 - 杜克大学和 UTSW 合作
  • 批准号:
    10488237
  • 财政年份:
    2021
  • 资助金额:
    $ 37.7万
  • 项目类别:
Administrative Core
行政核心
  • 批准号:
    10305566
  • 财政年份:
    2021
  • 资助金额:
    $ 37.7万
  • 项目类别:
6-thio-2'-deoxyguanosine in GBM: Pre-clinical Evaluation of Mechanism of action, Efficacy and Biomarker identification
GBM 中的 6-硫代-2-脱氧鸟苷:作用机制、功效和生物标志物鉴定的临床前评估
  • 批准号:
    10305568
  • 财政年份:
    2021
  • 资助金额:
    $ 37.7万
  • 项目类别:
Is Low Tumor Mutational Burden Predictive of Response to Oncolytic Polio Virus Therapy in Recurrent Glioblastoma?
低肿瘤突变负荷是否可以预测复发性胶质母细胞瘤对溶瘤脊髓灰质炎病毒治疗的反应?
  • 批准号:
    9807277
  • 财政年份:
    2019
  • 资助金额:
    $ 37.7万
  • 项目类别:
Experimental Therapy for Brain Tumors
脑肿瘤的实验治疗
  • 批准号:
    10005980
  • 财政年份:
    2018
  • 资助金额:
    $ 37.7万
  • 项目类别:
Career Development Program
职业发展计划
  • 批准号:
    9546619
  • 财政年份:
    2018
  • 资助金额:
    $ 37.7万
  • 项目类别:

相似海外基金

Single-cell analysis of adaptive immune system cells in IBD patients
IBD 患者适应性免疫系统细胞的单细胞分析
  • 批准号:
    22KJ2212
  • 财政年份:
    2023
  • 资助金额:
    $ 37.7万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Antigen presentation to the adaptive immune system in the choroid contributes to ocular autoimmune disease
脉络膜中的适应性免疫系统的抗原呈递导致眼部自身免疫性疾病
  • 批准号:
    10740465
  • 财政年份:
    2023
  • 资助金额:
    $ 37.7万
  • 项目类别:
Elucidation of the adaptive immune system in teleost fish
阐明硬骨鱼的适应性免疫系统
  • 批准号:
    22K05824
  • 财政年份:
    2022
  • 资助金额:
    $ 37.7万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Interaction of Galectin-9 and Pregnancy-Specific Glycoprotein 1 in the Regulation of Cells of the Innate and Adaptive Immune System
Galectin-9 和妊娠特异性糖蛋白 1 在先天性和适应性免疫系统细胞调节中的相互作用
  • 批准号:
    10434937
  • 财政年份:
    2021
  • 资助金额:
    $ 37.7万
  • 项目类别:
Peripheral Adaptive Immune System Changes Associated with Alzhiemer's Disease
与阿尔茨海默病相关的外周适应性免疫系统变化
  • 批准号:
    10194864
  • 财政年份:
    2021
  • 资助金额:
    $ 37.7万
  • 项目类别:
Interaction of Galectin-9 and Pregnancy-Specific Glycoprotein 1 in the Regulation of Cells of the Innate and Adaptive Immune System
Galectin-9 和妊娠特异性糖蛋白 1 在先天性和适应性免疫系统细胞调节中的相互作用
  • 批准号:
    10302501
  • 财政年份:
    2021
  • 资助金额:
    $ 37.7万
  • 项目类别:
Learning a molecular shape space for the adaptive immune system
学习适应性免疫系统的分子形状空间
  • 批准号:
    10275426
  • 财政年份:
    2021
  • 资助金额:
    $ 37.7万
  • 项目类别:
CAREER: Emergence of Functional Organization in the Adaptive Immune System
职业:适应性免疫系统中功能组织的出现
  • 批准号:
    2045054
  • 财政年份:
    2021
  • 资助金额:
    $ 37.7万
  • 项目类别:
    Continuing Grant
Learning a molecular shape space for the adaptive immune system
学习适应性免疫系统的分子形状空间
  • 批准号:
    10669709
  • 财政年份:
    2021
  • 资助金额:
    $ 37.7万
  • 项目类别:
Learning a molecular shape space for the adaptive immune system
学习适应性免疫系统的分子形状空间
  • 批准号:
    10467050
  • 财政年份:
    2021
  • 资助金额:
    $ 37.7万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了